Core Viewpoint - The company reported a revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - Profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - The earnings per share were HKD 0.1412, with an interim dividend of HKD 0.0975 per ordinary share [1] Revenue Performance - The revenue growth was primarily driven by strong sales performance of core brands, particularly the branded pharmaceutical segment's He Ji Gong and the traditional Chinese medicine segment's Bao Ji Wan [1] - Focused brand management and effective market promotion execution contributed to the sales performance [1] Business Segments - The Chinese medicine formula granules business showed stable performance, continuously contributing to the brand health business group [1]

Core Viewpoint - The company,健倍苗苗(02161), announced a mid-term dividend of HKD 0.0975 per share to be distributed on December 17, 2025 [1] Group 1 - The mid-term dividend reflects the company's ongoing commitment to returning value to shareholders [1]

Core Viewpoint - The company reported a significant increase in revenue and profit for the six months ending September 30, 2025, indicating strong financial performance compared to the previous year [1] Financial Performance - Revenue for the six months was approximately HKD 430 million, an increase of about 7.7% from approximately HKD 400 million in the same period of 2024 [1] - Operating profit for the same period was around HKD 150 million, reflecting a growth of approximately 23.8% from about HKD 122 million in 2024 [1] - Profit attributable to equity holders was approximately HKD 115 million, which is a 20.0% increase from around HKD 95.9 million in 2024 [1] Dividend Declaration - The board declared an interim dividend of HKD 0.0975 per ordinary share, totaling approximately HKD 8.01 million, which is an increase of about 77.3% compared to HKD 0.055 per ordinary share (totaling approximately HKD 45.2 million) in 2024 [1]

Core Viewpoint - The company reported a strong performance in its interim results for the six months ending September 30, 2025, with significant growth in revenue and profit driven by robust sales of its core brands [1] Financial Performance - Revenue reached approximately HKD 430 million, representing a year-on-year increase of about 7.7% [1] - Profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were HKD 0.1412, with an interim dividend of HKD 0.0975 per ordinary share [1] Business Segments - The growth in performance was primarily attributed to strong sales in the branded pharmaceutical segment, particularly the He Ji Gong brand, and the traditional Chinese medicine segment, especially the Bao Ji Wan product [1] - The company emphasized effective brand management and successful market promotion as key factors in driving sales [1] - The traditional Chinese medicine formula granules business also showed stable performance, contributing consistently to the overall health business group [1]

EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 健倍苗苗(保健 )有限公司 | | 股份代號 | 02161 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年九月三十日止六個月的中期股息 | | 公告日期 | 2025年11月17日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2026年3月31日 | | 宣派股息的報告期末 | 2025年9月30日 | | 宣派股息 | 每 股 0.0975 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.0975 HKD | | 匯率 | 1 HKD : ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) （於開曼群島註冊成立的有限公司） （股份代號：2161） | 截至九月三十日止六個月 | 二零二五年 | 二零二四年 | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 附 | 千港元 | 註 | 千港元 | | | | | | | | | | | | | | | | | 429,644 | 398,953 | 收 | 益 | 4 | | | | | | | | | | | | | | | | (176,043 ...

Core Viewpoint - The company, Jianbei Miao Miao (02161.HK), has announced a board meeting scheduled for November 17, 2025, to consider and approve its interim results for the six months ending September 30, 2025, and to discuss the potential declaration of an interim dividend, among other matters [1] Group 1 - The board meeting will focus on the interim performance of the company and its subsidiaries [1] - The meeting will also address the recommendation for an interim dividend, if applicable [1] - The date of the board meeting is set for November 17, 2025 [1]

公司秘書 董事會召開日期 健倍苗苗（保 健）有限公司（「本公司」）董事會（「董事會」）兹通告謹定於二零二五 年十一月十七日（星 期 一）舉 行 董 事 會 會 議，藉 以 考 慮 及 通 過 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 九 月 三 十 日 止 的 六 個 月 中 期 業 績 以 供 發 佈，並 考 慮 建 議 派 發中期股息（如 有），以 及 處 理 其 他 事 項。 承董事會命 健倍苗苗（保 健）有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) （於開曼群島註冊成立的有限公司） （股份代號：2161） 余振球 香 港，二 零 二 五 年 十 一 月 五 日 於 本 公 告 日 期，董 事 會 由 執 行 董 事 岑 廣 業 先 生（亦 為 主 席）、嚴 振 亮 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健培苗苗(保健)有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月3日 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02161 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 822,000,000 | | | | 822,000,000 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 822,000,000 | | 0 | | 822,000,000 | 第 2 頁 共 10 頁 v 1.1.1 III.已發 ...

Core Viewpoint - Jacobson Pharma and Genetron Holdings announced a new licensing agreement with Europharma, which will provide manufacturing space for Genetron in Hong Kong, effective from December 1, 2025, to January 27, 2028, with a monthly fee of HKD 247,000 [1] Group 1 - The 2025 Europharma licensing agreement is established due to the expiration of a previous licensing agreement in November 2025 [1] - Europharma is a wholly-owned subsidiary of Jacobson Pharma, while Europharma (Hong Kong) is a wholly-owned subsidiary of Genetron Holdings [1] - Since 2007, Europharma has been leasing factory space in the Science Park for pharmaceutical manufacturing [1] Group 2 - The new licensing arrangement will generate rental income from unused factory space for Europharma and provide suitable manufacturing facilities for Europharma (Hong Kong) [1] - Relocating Europharma (Hong Kong)'s existing facilities that comply with pharmaceutical production quality management standards is costly and time-consuming [1] - The 2025 Europharma licensing agreement allows Europharma (Hong Kong) to continue operations without interruption and avoid relocation expenses [1]